



EryDel to Present at the UBS Global Healthcare Conference 2018

Bresso (Milano), Italy – May 14, 2018 – EryDel SpA, a biotech company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced that Chief Executive Officer, Luca Benatti, will present at the UBS Global Healthcare Conference.

The presentation will take place at 11.30 a.m. EST on Monday, May 21, 2018 at the Grand Hyatt Hotel, 109 East 42nd Street, New York City.

About EryDel

EryDel SpA is a biotechnology company specialized in the development of drugs delivered through red blood cells (RBCs) by using a proprietary medical device technology. Its most advanced product, EryDex System (EDS) is under late stage development for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. EryDex has received Orphan Drug designation for the treatment of AT both from the FDA and the EMA. A completed pilot Phase II trial in AT patients demonstrated statistically significant efficacy of EDS on both the primary and secondary efficacy measures. An international multi-center, Phase III pivotal study, ATTeST, is being conducted. EryDel has a pipeline of preclinical programs that use its proprietary RBC's delivery technology for the treatment of other rare diseases.

The ATTeST project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 667946".

Media contact: Emanuela Germi at +39 02 36504470 or emanuela.germi@erydel.com